Fixed Duration Dosing of MONJUVI + rituximab and lenalidomide (R2)1
- MONJUVI should be administered by a healthcare professional with immediate access to emergency equipment and appropriate medical support to manage IRRs
- The recommended dose of MONJUVI is 12 mg/kg based on actual body weight administered as an intravenous infusion according to the dosing schedule in the table below
- Administer MONJUVI in combination with rituximab 375 mg/m2 (Cycles 1 to 5) and lenalidomide 20 mg (Days 1-21 in Cycles 1 to 12)
- Refer to the rituximab Prescribing Information and the lenalidomide Prescribing Information for the respective dosage recommendations
- Administer MONJUVI as an intravenous infusion- For the first infusion, use an infusion rate of 70 mL/h for the first 30 minutes; then, increase the rate so that the infusion is administered within 1.5 to 2.5 hours
- Administer all subsequent infusions within 1.5 to 2 hours
 
See Recommended Premedications for more information about MONJUVI premedications.
| Cycle 1 | |
| MONJUVI (QW) 12 mg/kg IV on days 1, 8, 15, and 22 | |
| Lenalidomide 20 mg/day PO on days 1-21 | |
| Rituximab (QW) 375 mg/m2 IV on days 1, 8, 15, and 22 | |
| Cycles 2-3 | |
| MONJUVI (QW) 12 mg/kg IV on days 1, 8, 15, and 22 | |
| Lenalidomide 20 mg/day PO on days 1-21 of each cycle | |
| Rituximab (QW) 375 mg/m2 IV on day 1 of each cycle | |
| Cycles 4-5 | |
| MONJUVI (Q2W) 12 mg/kg IV on days 1 and 15 | |
| Lenalidomide 20 mg/day PO on days 1-21 of each cycle | |
| Rituximab (Q4W) 375 mg/m2 IV on day 1 of each cycle | |
| Cycles 6-12 | |
| MONJUVI (Q2W) 12 mg/kg IV on days 1 and 15 | |
| Lenalidomide 20 mg/day PO on days 1-21 of each cycle | |
| Treatment completion after 12 cycles | |
Refer to the rituximab Prescribing Information and the lenalidomide Prescribing information for the respective dosage recommendations, including lenalidomide dosage recommendations for patients with renal insufficiency.
MONJUVI is a 12-cycle fixed
duration treatment1
MONJUVI + R2 can be administered
in a local outpatient setting without
hospitalization required1
MONJUVI should be administered by a healthcare professional with immediate access to emergency equipment and appropriate medical support to manage infusion-related reactions.1 For details on dose modifications and management of adverse reactions for IRRs and myelosuppression, please refer to the full Prescribing Information.
*Recommended dose of MONJUVI is based on the patient’s actual body weight.1
